Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing the Efficacy and Safety of Optimal Neoadjuvant to Adjuvant Anti-HER2- Based Therapy in Nigerian Women With HER2+ Breast Cancer

NCT06348134 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT06348134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06348134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing the Efficacy and Safety of Optimal Neoadjuvant to Adjuvant Anti-HER2- Based Therapy in Nigerian Women With HER2+ Breast Cancer
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Recruiting
Start date
March 18, 2025
Completion date
July 1, 2036
Enrollment
74 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2-positive breast cancer, human epidermal growth factor 2 negative carcinoma of breast